Premium
Endocrine gland‐derived vascular endothelial growth factor (EG‐VEGF) expression in colorectal cancer
Author(s) -
Nagano Hideki,
Goi Takanori,
Koneri Kenji,
Hirono Yasuo,
Katayama Kanji,
Yamaguchi Akio
Publication year - 2007
Publication title -
journal of surgical oncology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.201
H-Index - 111
eISSN - 1096-9098
pISSN - 0022-4790
DOI - 10.1002/jso.20716
Subject(s) - vascular endothelial growth factor , angiogenesis , colorectal cancer , medicine , metastasis , vascular endothelial growth factor a , cancer research , cancer , oncology , endocrine system , pathology , vegf receptors , hormone
Abstract Background and Objectives: Vascular endothelial growth factor (VEGF) is known as an important factor in the growth and metastasis of cancer cells. In 2001, a novel angiogenesis factor, endocrine gland‐derived vascular endothelial growth factor (EG‐VEGF), was cloned. In this study, we investigated the expression of EG‐VEGF in colorectal cancer, the relationship between its expression and clinicopathological factors, and the in vitro activity of EG‐VEGF transfectants. Methods: We determined expression levels of EG‐VEGF in 113 advanced colorectal cancers resected in our hospital by quantitative PCR, and compared the expression levels and clinicopathological findings by multivariate analyses. Results: The expression of EG‐VEGF mRNA was positive in 31 cancers and negative in 82 cancers. We found that compared with the negative expression of the EG‐VEGF gene, its positive expression was more frequently associated with hematogenous metastasis, and was associated with a poorer survival rate. In addition, EG‐VEGF transfectants showed a higher degree of in vitro tubular formation than control cells. Conclusions: We speculate that, in colorectal cancers, the EG‐VEGF gene functions as an important factor in angiogenesis in primary and metastatic lesions, and consider that it is useful as a novel prognostic factor. EG‐VEGF molecule‐targeted therapy has the potential for improving survival rates. J. Surg. Oncol. 2007;96:605–610. © 2007 Wiley‐Liss, Inc.